




1H 2019 Results

July 2019

Group structure *as of 30 June 2019*



Businesses	<i>Healthcare group specialized in long term care (nursing homes/rehab), diagnostics and cancer care</i>	<i>Global automotive supplier of suspensions, filtration, air intake & cooling components</i>	<i>Italian media group, with presence in dailies, periodicals, radio, internet and advertising</i>	<i>Investments in Private equity, NPLs</i>
Competitive position	<i>Leader in Italian long term care, developing presence in UK, India</i>	<i>Leadership positions in core geographies (Europe and South America), leveraged to expand globally</i>	<i>First Italian publishing group:</i> <ul style="list-style-type: none"> ▪ N.1 in national and local dailies circulation ▪ N.1 Information website ▪ N.1 news magazine ▪ N. 3 Radio network 	

Note: Participation stakes updated as of 30 June 2019 and calculated net of treasury shares of subsidiaries



CIR – Cofide Merger (1/2)

- On July 19, 2019 the Extraordinary Shareholders Meetings of CIR and Cofide approved the merger by incorporation of CIR into Cofide
- The transaction has the following objectives:
 - Shortening the control chain and achieving a corporate structure that is in line with best practices and market expectations
 - Increasing the free float, with positive impacts on trading and liquidity
 - Simplifying the Group's Corporate Governance and reducing overall holding costs
- The company resulting from the merger will be called CIR, and will have the same operational and strategic profile, as well as substantially the same financial position of today's CIR
- The exchange ratio for the merger has been set at 2.01 shares of Cofide for each share of CIR, based on a valuation methodology that included both NAV values and market prices of the two companies, in line with best market practices and previous comparable transactions. Such exchange ratio has been validated by the Related Parties Committees of CIR and Cofide, based on fairness opinions released by their respective independent financial advisors
- The merger is expected to be effective starting from January 2020. Following the completion of the merger, a Shareholders Meeting of the combined entity will promptly be called, in order to appoint a new Board of Directors

- Double voting rights in the post merger entity
 - Cofide's current by-laws include a double voting rights mechanism for shareholders that apply for it and continuously hold shares for a 'Minimum Holding Period' of 24 months
 - On April 29, 2019 the Shareholders meeting of Cofide approved a resolution for the extension of the Minimum Holding Period from 24 to 48 months
 - Such extension would take effect 30 days after the merger date with CIR, thereby giving current CIR shareholders a time window to apply for double voting rights based on the current 24 months Minimum Holding Period

1H 2019 consolidated financials highlights

- Consolidated net result in 1H 2019: € 2.0 M (vs € 24.1 M in 1H 2018)
Contribution of industrial businesses (KOS, Sogefi and GEDI): € 3.7 M (vs. € 20.2 M in 1H 2018)
- Consolidated net financial position at June 30, 2019:

Without IFRS16: - € 357.4 M (vs. - € 297.1 M at December 31, 2018), including:

- A net financial surplus at holding level of € 325.3 M
(stable vs. € 325.5 M at December 31, 2018)
- A net debt of consolidated subsidiaries of € 682.7 M
(increasing vs. € 622.6 M at December 31 2018 mainly due to GEDI and KOS).

With IFRS16: - € 800.6 M (of which -€ 1,125.3 M from subsidiaries)

Consolidated income statement



€ M

	1H 2018	1H 2019 w/o IFRS 16		1H 2019 with IFRS 16
Revenues	1,404.6	1,362.0	-3.0%	1,362.0
EBITDA	158.8	131.0	-17.5%	161.3
EBIT	76.0	49.1	-35.4%	51.5
Financial result	(16.2)	(12.9)		(19.2)
Taxes	(20.8)	(16.5)		(15.7)
Assets held for sale	3.0	(13.3) ⁽¹⁾		(13.3)
Group net result⁽²⁾	24.1	3.6		2.0⁽³⁾

(1) Composed of € -17.3 M write-down of Persidera asset, following alignment to divestment value, and € +4 M impact of divestment of Fraise plant by Sogefi

(2) Net of third party interests (equal to € -2.7 M in 1H 2019 w/o IFRS 16, € -1.3 M in 1H 2019 with IFRS 16 and € -18.4 M in 1H 2018)

(3) 1H 2019 normalized net result at € 13.5 M, before non-recurring write-downs (€ -7.9 M pro-quota impact of the Persidera write-down), effect of IFRS 16 (€ -1.6 M) and costs of the merger plan at the holding level

Consolidated income statement by business sector

€ M

	1H 2018	1H 2019
KOS Group	9.8	8.5
Sogefi Group	8.4	3.9
GEDI Group	2.0	(8.7)
Total operating companies⁽¹⁾	20.2	3.7
CIR holding ⁽²⁾	(3.9)	(1.7)
Net result	24.1	2.0

(1) Pro-rata share of subsidiaries' net result

(2) Including income from financial assets/non core investments, operating costs

Consolidated balance sheet – main group assets

€ M

Group equity in consolidated balance sheet	31 Dec. 2018	30 June 2019
KOS	174.4	162.1
Sogefi	111.5	112.8
GEDI	239.2	230.7
Total operating companies	525.1	505.6
Fixed assets	15.5	17.8
Private equity ⁽¹⁾	46.0	42.8
Non performing loans	10.0	10.0
Other investments	16.5	10.7
Other Assets (Liabilities)	(2.4)	(3.1)
Net cash	325.5	324.7
Total CIR holding level	411.1	402.9
Total CIR Group shareholders' equity	936.2	908.5
Shareholder's equity per share	1.18	1.14
Shareholder's equity per share (net of treasury shares) ⁽²⁾	1.45	1.42

(1) Book value decreasing mainly due to cash reimbursements to CIR and fair value adjustments

(2) Treasury shares as of 30 June 2019: n. 153.1 m, equal to 19.3% of share capital

Consolidated net financial position

€ M


	31 Dec. 2018	30 June 2019 w/o IFRS 16	30 June 2019 with IFRS 16
KOS Group	(259.4)	(292.7)	(609.8)
Sogefi Group	(260.5)	(267.3)	(331.7)
GEDI Group	(103.2)	(123.1)	(184.4)
Other subsidiaries	0.5	0.6	0.6
Total subsidiaries net financial indebtedness	(622.6)	(682.7)	(1,125.3)
CIR holding level	325.5	325.3	324.7
Consolidated net financial indebtedness	(297.1)	(357.4)	(800.6)
Total shareholders' equity ⁽¹⁾	1,448.9		1,402.3
Consolidated net invested capital	1,746.0		2,202.9

(1) Including third party interests

Net financial position at CIR Holding level

- Slight increase of net cash at CIR financial holdings is mainly due to the positive financial results in the period

Evolution of net financial position in 1H 2019



(1) Private equity investments

(2) Delta Fair value of securities + securities income, trading

(3) Operating costs, taxes, etc.


Composition of liquid assets

€ M

	31 Dec. 2018	30 June 2019
Cash and time deposits	19.6	9.2
Corporate bonds	10.8	11.0
Fixed income funds	253.2	258.3
Equity funds	--	--
Hedge funds	37.9	45.5
Other ⁽¹⁾	4.0	1.4
Total liquid assets	325.5	325.4
Gross financial debt	--	(0.7)
Net financial position	325.5	324.7

(1) Fair value derivatives

Liquid assets at 30 June 2019



1H 2019 Subsidiaries' financial and operational highlights



	1H 2019 Highlights	Key strategic objectives
KOS	<ul style="list-style-type: none"> Continuing growth of revenues (+4.4%), thanks to ongoing organic expansion, greenfield development and acquisitions 	<ul style="list-style-type: none"> Further consolidation in Long Term Care, with a primary focus on Italy, plus international diversification Focused geographical expansion in Diagnostics and Cancer care
Sogefi	<ul style="list-style-type: none"> SOGEFI outperformed the market in 1H2019, with revenues down 3.0% at constant exchange rates, vs Global car production -6,7% EBITDA at € 86.4 M, down from € 95.3 M in 1HQ2018, reflecting lower volumes Net debt substantially flat before the introduction of IFRS16, with slightly negative cash flow due to lower business performance 	<ul style="list-style-type: none"> Expansion of geographical coverage, through growth initiatives focused on Asia and North America Further efficiency improvement and optimisation of production footprint Product innovation, to capture new market opportunities
GEDI	<ul style="list-style-type: none"> Persisting press market weakness: newspapers circulation -7.7% (including digital copies -6.8%); press advertising market -12.6% (with newspapers -10.6%) Market growth only in Radio (+2.2%) and digital advertising (+2% excluding Search&Social) GEDI revenues were down 6.1%, better than the market; revenues from digital activities accounted for 12.2% of consolidated revenues, with digital subscribers reaching 119K As a result of revenues decline, operating profit was lower than in 1H2018, despite continuing cost reduction, which is expected to produce full effects later in the year 	<ul style="list-style-type: none"> Expansion of digital platforms, leveraging on leadership in traditional media Further efficiency improvement
Non-core investments	<ul style="list-style-type: none"> Ongoing realisation of Private Equity and NPL investments 	<ul style="list-style-type: none"> Realisation of existing assets Selective approach on new investments

KOS - Overview


KOS is the leading operator in Italian Long Term Care (Nursing Homes, Rehabilitation and Psychiatric Care), with:

- ≈8.000 beds in 84 facilities, with a premium offering
- Coverage of the most attractive Italian regions, plus 1 Rehab JV in India


KOS also operates in the Diagnostics & Cancer care business (D&CC) through Medipass:

- Main activity is providing medical and technological outsourcing services to hospitals
- Recently started operating own Cancer Care Centers and Hospitals
- Core markets are Italy and India, presence in UK

In Acute Care, KOS manages one public hospital in Suzzara



2018 Revenues breakdown




KOS – Reference Market: Italian Long Term Care

Composition of Long Term Care expenditure

Funding source	% of GDP	Euro Bn
LTC public expenditure	0,8%	13,63
Social Security	0,8%	13,63
Cash Benefit	0,2%	2,85
Total LTC Expenditure	1,8%	30,1

Long Term Care expenditure forecast (% of GDP)



Public spending on Long Term Care (65+) remained stable in recent years despite spending reviews on other Healthcare sectors in Italy, as Government tried to substitute Acute Care treatments with less expensive LTC ones

LTC expenditure is expected to grow steadily in the long run, due to the aging population trend

KOS – Strong Barriers to Entry

The NHS operates through public, private and non-profit accredited entities.

All private and non profit entities are regulated at regional level and must comply with:

- **Authorisation**: basic requirement for operating any healthcare facility (minimum structural, technological and organisational requirements)
- **Accreditation**: granted by Regions to authorised facilities, in order to act for the account of the NHS (additional qualification requirements, e.g.: patient rooms standards, minimum minute count for patient treatments, personnel training obligations, ...)
- **Contract**: yearly agreement between Regions or Local Healthcare Units (ASL) and accredited entities, specifying:
 - Services to be rendered for the account of the NHS
 - Yearly budget for envisaged services

Strong barriers to entry

- **Multiple counterparties (Regions, ASLs) to interact with, local presence fundamental to anticipate/meet upcoming healthcare needs**
- **Complex regulatory framework, widely diversified across Regions**
- **Rigorous, detailed and diversified healthcare and lodging standard requirements to operate facilities**
- **Relationship with Regions based on trust, reputation and expertise built over the years**

KOS – Key Financials

Historic Performance

€ M	FY2014	FY2015	FY2016	FY2017	FY2018	CAGR
Number of beds	6.404	7.257	7.347	7.764	8.157	
Revenues	392.4	439.2	461.1	490.6	544.9	+ 8,6%
EBITDAR	85.8	102.1	111.7	119.7	137.1	+12,4%
EBITDA	60.4	73.0	82.4	87.8	101.8	+13,9%
Net result	13.7	21.4	24.6	30.7	36.3	
NFP	(157.0)	(210.0)	(213.6)	(237.1)	(259.4)	

Current Trading

1H 2018	1H 2019 w/o IFRS 16	1H 2019 with IFRS 16
269.5	281.3	281.3
66.7	67.0	67.0
49.1	48.8	65.9
16.5	15.5	14.4
(279.0)	(292.7)	(609.8)

KOS Growth Strategy

KOS has profitably grown since its startup by CIR in 2003, by focusing and developing excellence in two core activities:

LTC

- KOS pursued market consolidation in the core domestic market in Nursing Homes, Rehabilitation and Psychiatry, at a pace of 400-500 beds per year, through both acquisitions and greenfield projects
- Focus is on the acquisition of high quality assets, to be further improved both from a qualitative and financial point of view, by leveraging on distinctive know how and economies of scale (EBITDA margin from 9.5% to 18.7% over the last 4 years)
- KOS recently started considering other European LTC markets, to seek additional growth opportunities and further leverage its know how


D&CC

- Medipass started offering medical and tech services in Diagnostics in Italy; later expanded in the high growth Cancer Care segment and started operating own centers
- Leveraging on its leadership position in Italy, Medipass started an international expansion focused on the high growth Indian market

1H 2019 Performance and outlook

- Revenues grew 4,4%, thanks mainly to organic growth across all business lines, as well as acquisitions and greenfield projects completed in 2018
- EBITDA at 17.3% of total revenues
- NFP in 1H 2019 was impacted by 35M dividend distribution and 20M development Capex, largely funded by operational cash flow
- The different accounting treatment of KOS' facilities rents under IFRS16 substantially increases EBITDA (ca. 35M on an annual basis) as well as the Net Financial Position (ca. 325M), but without any effect on covenant calculation

Sogefi - overview



2018 Revenues breakdown

Customers		Regions	
RENAULT/NISSAN	11.5%	Europe	61.0%
PSA	11.2%	North America	18.1%
FCA/CNH Industrial	10.9%	South America	11.2%
FORD	10.8%	Asia	9.7%
DAIMLER	9.0%		
GM	8.7%		
VOLKSWAGEN/AUDI	5.0%		
TOYOTA	3.2%		
BMW	2.9%		
OTHER	26.8%		


Key financials

€ M	1H 2018	1H 2019 w/o IFRS 16	1H 2019 with IFRS 16
Revenues	812.6	777.8	777.8
EBITDA	95.3	80.3	86.3
Net result	14.8	8.0	6.9

1Q 2019 Performance and outlook

- Global automotive market production decreased 6.7% in 1H2019: Europe -6.1%, Asia -12.4%, North America -2.7% and South America -3.2% (mainly due to Argentina -33%)
- Sogefi's revenues were down -3.0% at constant exchange rates (-4.3% at historical exchange rates), outperforming the market (Europe -3.3%, North America -3.7% and Asia -14% while Sud America recorded +11%)
- EBITDA at € 86.4 (down from € 95.3 M in 1H 2018), due to lower volumes
- Net income includes a profit of € 4 M related to the sale of the Fraize plant by the Air&Cooling division
- Free Cash Flow was -€ 8.8 M, decreasing vs. +€ 3.9 M in 1H 2018, impacted mainly by € 5.4 M IFRS 16 effects and by the lower business performance
- Net debt w/o IFRS 16 was € 267.3 M (vs € 260.5 M in 4Q2018), while with IFRS16 it stood at € 332.1 M
- In 2H 2019, the global automotive market is expected to decline vs. previous year (although less than in 1H). Sogefi expects revenues substantially in line with 2H 2018 and a slightly improving EBIT margin compared to 1H 2019

GEDI – overview



Circulation revenues (% of 2018 total)

Advertising revenues, including digital (12% of 2018 total); for Manzoni Third party advertising collection

(*) TV Network operator, 30% stake, pending sale completion

(**) ITEDI consolidated from 3Q2017

(***) including Persidera write-down at financial charges level

Key financials

€ M	1H 2018	1H 2019 w/o IFRS 16	1H 2019 with IFRS16
Revenues	322.5	302.9	302.9
EBITDA	22.1	13.0	20.2
Net result	4.3	(18.4)	(19.1)

1Q 2019 Performance and outlook

- On June 5, 2019 GEDI announced the sale of its 30% stake in Persidera to F2i and Ei Towers, for a total consideration of € 74.5 M
- Circulation revenues at € 134.5 M (-5.2%) in a market down 7.7% .
- Advertising revenues at € 147.3 M (-7.4%):
 - press advertising down by -10.6% (vs. market -12.6%)
 - digital advertising -5.3% (vs. market + 2.0%)
 - radio reported a -0.9% decrease (vs. market + 2.2%)
- Costs are 5.5% lower vs 1H 2018, but still do not fully reflect the ongoing restructuring of La Repubblica's newsroom (from March) and the closure of two printing facilities (from April)
- As a consequence of the weak top line, EBITDA and EBIT were lower than in 1H 2018
- Net result at -€ 19.1 M, mainly due to the - € 16.9 M write-down of Persidera
- Net debt w/o IFRS 16 at € 123.1 M vs. € 103.2 M at the end of 2018, due to restructuring plan cash expenditures and working capital trends. Net debt with IFRS16 stood at € 184.4 M
- As for the 2019 outlook, evidence available to date suggests persisting weak market trends. In such a challenging market, in order to preserve profitability GEDI will continue to implement cost reduction measures, to further exploit synergies from the merger with ITEDI and strengthen its leadership in digital activities

Non-core investments

Private equity

- Diversified portfolio of private equity funds and direct minority private equity investments, with a fair value of € 42.8 M at 30 June 2019 (with declining trend mainly due to reimbursements and fair value adjustments)
- The portfolio has reached its maturity/reimbursement phase, as limited investments were added in the recent past

Other Investments

- Other non strategic investments include direct minority stakes with a value of € 10.7 M at 31 March 2019, decreasing vs € 16.5M at 4Q 2018 due to divestments

NPL

- The net value of the non-performing loan assets was stable at € 10.0 M at 30 June 2019
- CIR no longer owns operating companies in this industry and is currently in the process of collecting the remaining receivables, with no further investments

Disclaimer



- *This document has been prepared by CIR for information purposes only and for use in presentations of the Group's results and strategies.*
- *For further details on CIR and its Group, reference should be made to publicly available information, including the Annual Report, the Semi-Annual and Quarterly Reports*
- *Statements contained in this document, particularly the ones regarding any CIR Group possible or assumed future performance, are or may be forward looking statements and in this respect they involve some risks and uncertainties*
- *Any reference to past performance of CIR Group shall not be taken as an indication of future performance*
- *This document does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever*



www.cirgroup.com